|
|
 |
|
Viewing report
|
|
|
|
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Global Industry Analysts, Inc, May 2008, Pages: 530
This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, & Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 87 companies including many key and niche players worldwide such as Boehringer Ingelheim, Bristol-Myers Squibb Co., Eisai Inc., Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Novartis AG, Ortho-McNeil Neurologics, Inc., Pfizer Inc., Roche, Shire Pharmaceuticals Group PLC, and Valeant Pharmaceuticals International. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
|
|
|
|
